Engineered heart tissues made from human pluripotent stem cell-derived cardiomyocytes have been used for modeling cardiac pathologies, screening new therapeutics, and providing replacement cardiac tissue. Current methods measure the functional performance of engineered heart tissue by their twitch force and beating frequency, typically obtained by optical measurements. In this article, we describe a novel method for assessing twitch force and beating frequency of engineered heart tissue using magnetic field sensing, which enables multiple tissues to be measured simultaneously. The tissues are formed as thin structures suspended between two silicone posts, where one post is rigid and another is flexible and contains an embedded magnet. When the tissue contracts it causes the flexible post to bend in proportion to its twitch force. We measured the bending of the post using giant magnetoresistive (GMR) sensors located underneath a 24-well plate containing the tissues. We validated the accuracy of the readings from the GMR sensors against optical measurements. We demonstrated the utility and sensitivity of our approach by testing the effects of three concentrations of isoproterenol and verapamil on twitch force and beating frequency in real-time, parallel experiments. This system should be scalable beyond the 24-well format, enabling greater automation in assessing the contractile function of cardiomyocytes in a tissue-engineered environment.
Get full access to this article
View all access options for this article.
References
1.
KarantalisV., BalkanW., SchulmanI.H., HatzistergosK.E., and HareJ.M.Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol, 303, 2012.
2.
SuncionV.Y., SchulmanI.H., and HareJ.M.Concise review: the role of clinical trials in deciphering mechanisms of action of cardiac cell-based therapy. Stem Cells Transl Med, 1, 2012.
3.
KawamuraM., MiyagawaS., MikiK., SaitoA., FukushimaS., HiguchiT., KawamuraT., KurataniT., DaimonT., ShimizuT., OkanoT., and SawaY.Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation, 126, 2012.
4.
MauritzC., MartensA., RojasS.V., SchnickT., RathertC., ScheckerN., MenkeS., GlageS., ZweigerdtR., HaverichA., MartinU., and KutschkaI.Induced pluripotent stem cell (ipsc)-derived flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute myocardial infarction. Eur Heart J, 32, 2011.
5.
SinglaD.K., LongX., GlassC., SinglaR.D., and YanB.Induced pluripotent stem (ips) cells repair and regenerate infarcted myocardium. Mol Pharm, 8, 2011.
6.
MosnaF., AnnunziatoF., PizzoloG., and KramperaM.Cell therapy for cardiac regeneration after myocardial infarct: which cell is the best? Cardiovasc Hematol Agents Med Chem, 8, 2010.
7.
FreundC., and MummeryC.L.Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models. J Cell Biochem, 107, 2009.
8.
BellinM., MarchettoM.C., GageF.H., and MummeryC.L.Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol, 13, 2012.
9.
GrskovicM., JavaherianA., StruloviciB., and DaleyG.Q.Induced pluripotent stem cells—opportunities for disease modelling and drug discovery. Nat Rev Drug Discov, 10, 2011.
10.
DambrotC., PassierR., AtsmaD., and MummeryC.L.Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models. Biochem J, 434, 2011.
11.
DasA.K., and PalR.Induced pluripotent stem cells (ipscs): the emergence of a new champion in stem cell technology-driven biomedical applications. J Tissue Eng Regen Med, 4, 2010.
12.
MercolaM., ColasA., and WillemsE.Induced pluripotent stem cells in cardiovascular drug discovery. Circ Res, 112, 2013.
13.
TzatzalosE., AbilezO.J., ShuklaP., and WuJ.C.Engineered heart tissues and induced pluripotent stem cells: macro- and microstructures for disease modeling, drug screening, and translational studies. Adv Drug Deliv Rev, 96, 2016.
14.
EderA., VollertI., HansenA., and EschenhagenT.Human engineered heart tissue as a model system for drug testing. Adv Drug Deliv Rev, 96, 214, 2016.
15.
ZimmermannW.-H., MelnychenkoI., and EschenhagenT.Engineered heart tissue for regeneration of diseased hearts. Biomaterials, 25, 1639, 2004.
16.
HirtM.N., HansenA., and EschenhagenT.Cardiac tissue engineering: state of the art. Circ Res, 114, 354, 2014.
17.
TiburcyM., and ZimmermannW.-H.Modeling myocardial growth and hypertrophy in engineered heart muscle. Trends Cardiovasc Med, 24, 7, 2014.
MathurA., LoskillP., ShaoK., HuebschN., HongS., MarcusS.G., MarksN., MandegarM., ConklinB.R., and LeeL.P.Human ipsc-based cardiac microphysiological system for drug screening applications. Sci Rep, 5, 8883, 2015.
23.
NavarreteE.G., LiangP., LanF., Sanchez-FreireV., SimmonsC., GongT., SharmaA., BurridgeP.W., PatlollaB., and LeeA.S.Screening drug-induced arrhythmia using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation, 128, S3, 2013.
24.
GrosbergA., AlfordP.W., McCainM.L., and ParkerK.K.Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip. Lab Chip, 11, 2011.
25.
AgarwalA., GossJ.A., ChoA., McCainM.L., and ParkerK.K.Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip, 13, 3599, 2013.
26.
ZhangD., ShadrinI.Y., LamJ., XianH.-Q., SnodgrassH.R., and BursacN.Tissue-engineered cardiac patch for advanced functional maturation of human esc-derived cardiomyocytes. Biomaterials, 34, 5813, 2013.
27.
HayakawaT., KunihiroT., AndoT., KobayashiS., MatsuiE., YadaH., KandaY., KurokawaJ., and FurukawaT.Image-based evaluation of contraction–relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: correlation and complementarity with extracellular electrophysiology. J Mol Cell Cardiol, 77, 178, 2014.
28.
AungA., BhullarI.S., TheprungsirikulJ., DaveyS.K., LimH.L., ChiuY.-J., MaX., DewanS., LoY.-H., and McCullochA.3d cardiac μtissues within a microfluidic device with real-time contractile stress readout. Lab on a Chip, 16, 153, 2016.
29.
TullochN.L., MuskheliV., RazumovaM.V., KorteF.S., RegnierM., HauchK.D., PabonL., ReineckeH., and MurryC.E.Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res, 109, 47, 2011.
30.
RuanJ.L., TullochN.L., SaigetM., PaigeS.L., RazumovaM.V., RegnierM., TungK.C., KellerG., PabonL., and ReineckeH.Mechanical stress promotes maturation of human myocardium from pluripotent stem cell‐derived progenitors. Stem Cells, 33, 2148, 2015.
31.
EschenhagenT., FinkC., RemmersU., ScholzH., WattchowJ., WeilJ., ZimmermannW., DohmenH., SchäferH., and BishopricN.Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J, 11, 683, 1997.
32.
BoudouT., LegantW.R., MuA., BorochinM.A., ThavandiranN., RadisicM., ZandstraP.W., EpsteinJ.A., MarguliesK.B., and ChenC.S.A microfabricated platform to measure and manipulate the mechanics of engineered cardiac microtissues. Tissue Eng Part A, 18, 910, 2011.
33.
SchaafS., ShibamiyaA., MeweM., EderA., StöhrA., HirtM.N., RauT., ZimmermannW.-H., ConradiL., and EschenhagenT.Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One, 6, e26397, 2011.
34.
StoehrA., NeuberC., BaldaufC., VollertI., FriedrichF.W., FlennerF., CarrierL., EderA., SchaafS., and HirtM.N.Automated analysis of contractile force and ca2+ transients in engineered heart tissue. Am J Physiol Heart Circ Physiol, 306, H1353, 2014.
35.
CoeyJ.M., Magnetism and Magnetic Materials. New York, NY: Cambridge University Press, 2010.
36.
LaflammeM.A., ChenK.Y., NaumovaA.V., MuskheliV., FugateJ.A., DuprasS.K., ReineckeH., XuC., HassanipourM., and PoliceS.Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol, 25, 1015, 2007.
37.
SchaafS., EderA., VollertI., StöhrA., HansenA., and EschenhagenT.Generation of strip-format fibrin-based engineered heart tissue (EHT). Methods Mol Biol, 1181, 121, 2014.
38.
RoeckleinB.A., and Torok-StorbB.Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus e6/e7 genes. Blood, 85, 997, 1995.
EndohM.The effects of various drugs on the myocardial inotropic response. Gen Pharmacol, 26, 1, 1995.
41.
SchoenI., HuW., KlotzschE., and VogelV.Probing cellular traction forces by micropillar arrays: contribution of substrate warping to pillar deflection. Nano Lett, 10, 1823, 2010.
42.
SchwingerR.H., BöhmM., and ErdmannE.Negative inotropic properties of isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardial tissue. J Cardiovasc Pharmacol, 15, 892, 1990.
43.
PillekampF., HausteinM., KhalilM., EmmelheinzM., NazzalR., AdelmannR., NguemoF., RubenchykO., PfannkucheK., and MatzkiesM.Contractile properties of early human embryonic stem cell-derived cardiomyocytes: beta-adrenergic stimulation induces positive chronotropy and lusitropy but not inotropy. Stem Cells Dev, 21, 2111, 2012.
44.
YangX., PabonL., and MurryC.E.Engineering adolescence maturation of human pluripotent stem cell–derived cardiomyocytes. Circ Res, 114, 511, 2014.
45.
NodaK., HoshinoK., MatsumotoK., and ShimoyamaI.A shear stress sensor for tactile sensing with the piezoresistive cantilever standing in elastic material. Sensor Actuat A-Phys, 127, 295, 2006.
46.
EvansB., ShieldsA., CarrollR.L., WashburnS., FalvoM., and SuperfineR.Magnetically actuated nanorod arrays as biomimetic cilia. Nano Lett, 7, 1428, 2007.
47.
SniadeckiN.J., AnguelouchA., YangM.T., LambC.M., LiuZ., KirschnerS.B., LiuY., ReichD.H., and ChenC.S.Magnetic microposts as an approach to apply forces to living cells. Proc Natl Acad Sci, 104, 14553, 2007.
48.
HeinM.A., MaqablehM.M., DelahuntM.J., TondraM., FlatauA.B., ShieldC.K., and StadlerB.J.Fabrication of bioinspired inorganic nanocilia sensors. IEEE Trans Magn, 49, 191, 2013.
49.
MehtaA., ChungY.Y., NgA., IskandarF., AtanS., WeiH., DustingG., SunW., WongP., and ShimW.Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells. Cardiovasc Res, 91, 577, 2011.
50.
HimmelH.M.Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds. J Pharmacol Toxicol Methods, 68, 97, 2013.
51.
GilchristK.H., LewisG.F., GayE.A., SellgrenK.L., and GregoS.High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays. Toxicol Appl Pharmacol, 288, 249, 2015.
52.
KimJ.J., YangL., LinB., ZhuX., SunB., KaplanA.D., BettG.C., RasmussonR.L., LondonB., and SalamaG.Mechanism of automaticity in cardiomyocytes derived from human induced pluripotent stem cells. J Mol Cell Cardiol, 81, 81, 2015.
53.
XiJ., KhalilM., ShishechianN., HannesT., PfannkucheK., LiangH., FatimaA., HausteinM., SuhrF., and BlochW.Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. FASEB J, 24, 2739, 2010.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
